Fetal and neonatal consequences of antenatal exposure to type 1 angiotensin II receptor-antagonists

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 18, Issue 2, 2005, Pages 137-140

  Vendemmia, Maria ^a   Garcia Méric, Patricia ^a   Rizzotti, Alina ^a   Boubred, Farid ^a   Lacroze, Valérie ^a   Liprandi, Agnès ^b   Simeoni, Umberto ^a  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Angiotensin II; Fetus; Infant; Kidney; Newborn; Sartan

Indexed keywords

ADRENALIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CLONIDINE; DOBUTAMINE; DOPAMINE; HYDROCHLOROTHIAZIDE; LECARDINIPINE; METHYLDOPA; NITRIC OXIDE; PROPRANOLOL; PROSTACYCLIN; SURFACTANT; UNCLASSIFIED DRUG; VALSARTAN;

ADULT; ARTICLE; CALVARIA; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG USE; FEMALE; FETUS; FETUS DISEASE; FETUS ECHOGRAPHY; FOLLOW UP; GESTATIONAL AGE; HISTOPATHOLOGY; HUMAN; HYPOCALVARIA; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; KIDNEY TUBULE DYSGENESIA; MALE; MATERNAL HYPERTENSION; NEWBORN; OLIGOHYDRAMNIOS; PREGNANCY TERMINATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY; SKULL MALFORMATION; SYMPTOM; THIRD TRIMESTER PREGNANCY;

ABNORMALITIES, MULTIPLE; ADULT; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERTENSION; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 27344436349     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050500217244     Document Type: Article

References (21)

1. Sung JC, White CM. Pharmacologic, pharmakocinetic and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy 2000;20:130-139.
2. Pride PG, Sedman AB, Nugent CE, Mason B. Angiotensin-converting enzyme inhibitor fetopathy. J Amer Soc Nephrol 1993;3:1575-1582.
3. Yoo KH, Wolstenholme JT, Chevalier RL. Angiotensin-converting enzyme inhibition decreases growth factor expression in the neonatal rat kidney. Pediatr Res 1997;42:588-592.
4. Briggs GG, Nageotte MP. Fatal fetal outcome with the combined use of Valsartan and Atenolol. Ann Pharmacother 2001;35:859-861.
5. Rosa FW, Bosco LA, Possum Graham C, Milstien JB, Dreis M, Creamer J. Neonatal anuria with maternal angiotensin-converting enzyme inhibition. Obstet Gynecol 1989;74:371-374.
6. Hannsens M, Keirse MJNC, Vankelecom F, Van Assche FA. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 1991;78:128-135.
7. Tabacova SA, Kimmel CA. Enalapril: pharmacokinetic/dynamic inferences for comparative developmental toxicity. Reproduct Toxicol 2001;15:467-478.
8. Buttar HS. An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development. Mol Cell Biochem 1997;176:61-71.
9. Robillard JE, Gomez RA, Van Orden D, Smith FG. Comparison of the adrenal and renal responses to angiotensin II in fetal lambs and adult sheep. Circ Res 1982;50:140-147.
10. Yosipiv IV, Dipp S, Ekdahr SS. Ontogeny of somatic angiotensin-converting enzyme. Hypertension 1994;23:369-374.
11. Moore KL, Persaud TVN. The developing human. Clinically oriented embryology. 5th ed. Philadelphia: WB Saunders; 1993.
12. Barr M. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994;50:399-409.
13. Saji H, Yamanaka M, Hagiwara A, Ljiri R. Losartan and fetal toxic effects. Lancet 2001;357:363.
14. Pietrement C, Malot L, Santerne B, et al. Neonatal acute renal failure secondary to maternal exposure to Telmisartan, angiotensin II receptor antagonist. J Perinatol 2003;23:254-255.
15. Chung NA, Lip GY, Beevers DG. Angiotensin-II-recpetor inhibitors in pregnancy. Lancet 2001;357:1620.
16. Martinovic J, Benachi A, Laurent N, Daïkha-Dahmane F, Gubler MC. Fetal toxic effects and angiotensin-II-receptor antagonits. Lancet 2001;358:24.
17. Schaefer C. Angiotensin II-receptor antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res Part A Clin Mol Teratol 2003;67:591-594.
18. Chow KM, Lam CM. Angiotensin II receptor antagonist in pregnancy. J Perinatol 2004;24:56-57.
19. Berkane N, Carlier P, Verstraete L, Mathieu E, Mathieu E, Heim N, Uzan S. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Res Part A Clin Mol Teratol 2004;70:547-549.
20. Spence SG, Allen HL, Cukierski MA, Manson JM, Robertson RT, Eydelloth RS. Denning the period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. Teratology 1995;51:367-382.
21. Muller PR, James A. Pregnancy with prolonged fetal exposure to an angiotensin-converting enzyme inhibitor. J Perinatol 2002;22:582-584.